Argireline vs Matrixyl
Argireline (acetyl hexapeptide-8) and Matrixyl (palmitoyl pentapeptide-4) are cosmetic peptide ingredients studied for different reasons: one for interference with SNARE complex assembly, the other as a matrix-signaling fragment. This page compares their structures, proposed mechanisms, evidence and analytics.
Argireline and Matrixyl are among the most widely used peptide ingredients in cosmetic formulations, listed on labels by their INCI names, acetyl hexapeptide-8 (formerly acetyl hexapeptide-3) and palmitoyl pentapeptide-4. They are cosmetic ingredients, not drugs, and are studied within cosmetic science rather than through clinical trials of medical conditions.
Their design rationales are different. Argireline is based on a fragment of the neuronal protein SNAP-25 and was proposed to interfere with the protein complex involved in neurotransmitter release. Matrixyl is a lipidated fragment of type I procollagen proposed to act as a signal for extracellular matrix synthesis. Comparing them illustrates the two main families of cosmetic peptides.
Side-by-side
| Attribute | Argireline | Matrixyl |
|---|---|---|
| INCI name | Acetyl hexapeptide-8 (formerly acetyl hexapeptide-3) | Palmitoyl pentapeptide-4 (formerly palmitoyl pentapeptide-3) |
| Sequence | Ac-Glu-Glu-Met-Gln-Arg-Arg-NH<sub>2</sub> | Palmitoyl-Lys-Thr-Thr-Lys-Ser (Pal-KTTKS) |
| Origin of sequence | N-terminal region of SNAP-25 | Fragment of the type I procollagen α1 chain |
| Modifications | N-acetyl, C-amide | N-terminal palmitoyl (C16) chain for lipophilicity |
| Proposed mechanism | Competes with SNAP-25 in SNARE complex assembly (in vitro) | Signals fibroblasts to increase collagen and matrix protein synthesis (in vitro) |
| Research category | Neurotransmitter-inhibitor type cosmetic peptide | Signal-type cosmetic peptide |
| Evidence level | In-vitro and small cosmetic studies | In-vitro and small cosmetic studies |
| Regulatory status | Cosmetic ingredient; not an approved drug | Cosmetic ingredient; not an approved drug |
| Analytical pitfalls | Methionine oxidation; counter-ion content | Hydrophobic lipid tail complicates HPLC and solubility; confusion with other Matrixyl-branded blends |
| Storage | Lyophilized at -20 °C, protected from light and oxygen | Lyophilized at -20 °C, protected from moisture |
Different design strategies
Argireline mimics the N-terminal end of SNAP-25, one of the proteins that assemble into the SNARE complex needed for vesicle fusion and neurotransmitter release. The idea, supported by in-vitro experiments, is that the hexapeptide competes for a place in that complex and reduces its formation. Matrixyl takes a different approach: the KTTKS sequence comes from type I procollagen, and fragments like it were proposed to act as feedback signals that prompt fibroblasts to make more collagen, fibronectin and related matrix components in cell culture.
Strength of the evidence
For both ingredients, the supporting data are mainly in-vitro assays and small cosmetic studies, often sponsored by ingredient manufacturers, measuring outcomes such as wrinkle depth by skin imaging. Independent, large, controlled studies are scarce. A key open question is skin penetration: Argireline is a charged, hydrophilic peptide, and the extent to which it reaches nerve terminals through intact skin is uncertain, while Matrixyl's palmitoyl chain was added to aid penetration. Cosmetic claims are not regulated in the same way as drug claims.
Analytical considerations
Argireline contains methionine, so oxidized material should be monitored by mass spectrometry, and its two arginines and two glutamates make counter-ion content significant. Matrixyl's palmitoyl group makes it far more hydrophobic than its pentapeptide would suggest, requiring HPLC conditions suited to lipopeptides; the mass must include the lipid. Matrixyl is also a trade name that covers more than one product, and a later blend sold under a related name contains different palmitoylated peptides, so certificates should name the specific INCI ingredient. Argireline is related to Snap-8, an extended octapeptide.
Frequently asked questions
What is the difference between Argireline and Matrixyl?
Argireline is acetyl hexapeptide-8, a fragment of the neuronal protein SNAP-25 proposed to interfere with SNARE complex assembly. Matrixyl is palmitoyl pentapeptide-4, a lipidated procollagen fragment proposed to signal fibroblasts to produce matrix proteins. They are both cosmetic ingredients, but their sequences, modifications and proposed mechanisms are unrelated.
Are Argireline and Matrixyl drugs?
No. Both are cosmetic ingredients identified by INCI names, not approved drugs, and they have not been evaluated by the FDA as medicines. Their supporting research consists mainly of cell-culture experiments and small cosmetic studies. Descriptions of their effects should be read as cosmetic-science findings, not as evidence of any medical effect.
Is Argireline the same as Snap-8?
No, though they are closely related. Snap-8 (acetyl octapeptide-3) extends the Argireline sequence by two residues at the C-terminus and was developed as a follow-up based on the same SNAP-25 fragment approach. The two have different lengths and masses, so a certificate of analysis should confirm which one was tested.
Full entries
- Argireline (acetyl hexapeptide-8)
Argireline is a cosmetic ingredient, acetyl hexapeptide-8 (formerly acetyl hexapeptide-3), a six-residue peptide modeled on the N-terminal region of the SNARE protein SNAP-25. It has been studied in vitro and in small cosmetic trials of expression lines.
- Matrixyl (palmitoyl pentapeptide-4)
Matrixyl is a cosmetic ingredient, palmitoyl pentapeptide-4 (Pal-KTTKS), consisting of the pentapeptide Lys-Thr-Thr-Lys-Ser linked to palmitic acid. Its research consists mainly of in-vitro collagen synthesis studies and small cosmetic studies of skin appearance.
Cite this page